Basel, Switzerland, November 16, 2026
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for adults with primary membranous nephropathy (pMN) who are at risk of disease progression, to induce remission of proteinuria. With this regulatory milestone, Gazyva/Gazyvaro becomes the first and only FDA-approved treatment specifically for primary membranous nephropathy, a rare and chronic autoimmune kidney disease that can cause progressive kidney damage and eventually lead to kidney failure. The approval represents a significant advancement in nephrology and provides a new targeted treatment option for patients who previously had limited disease-specific therapeutic choices. The regulatory decision is supported by positive results from the pivotal Phase III MAJESTY clinical trial, which demonstrated significantly higher complete proteinuria remission rates with obinutuzumab compared with tacrolimus after two years of treatment. The approval further strengthens Roche’s immunology portfolio and highlights the growing importance of targeted B-cell therapies in treating autoimmune kidney disorders.
FDA Approval Introduces First Treatment for Primary Membranous Nephropathy
Primary membranous nephropathy (pMN) is an autoimmune condition in which the body’s immune system attacks the glomeruli, the tiny filtering structures within the kidneys. This damage affects the kidneys’ ability to filter blood properly, allowing excessive amounts of protein to pass into the urine, a condition known as proteinuria. Patients may experience swelling (edema), fatigue and declining kidney function. If the disease remains uncontrolled, it can lead to serious complications, including chronic kidney damage, blood clots, cardiovascular problems and kidney failure. According to Roche, approximately 30% of untreated patients may progress to kidney failure within 10 years, demonstrating the importance of effective disease management. The newly approved treatment is designed to address an underlying immune mechanism involved in disease development. Gazyva/Gazyvaro contains obinutuzumab, a humanised monoclonal antibody targeting the CD20 protein on B cells. By targeting these immune cells, the medicine helps reduce abnormal B-cell activity associated with autoimmune disease. This targeted approach aims to control the immune response responsible for kidney injury and support the achievement of proteinuria remission. The FDA approval applies to adults with primary membranous nephropathy who are at risk of disease progression, with the treatment intended to induce remission of proteinuria.
Phase III MAJESTY Trial Demonstrates Superior Remission Rates
The FDA approval is supported by positive findings from the pivotal Phase III MAJESTY clinical trial (NCT04629248), which evaluated the efficacy and safety of obinutuzumab compared with tacrolimus in adults with primary membranous nephropathy. The randomized, open-label, multicentre study enrolled 142 adult patients, who were assigned in a 1:1 ratio to receive either Gazyva/Gazyvaro or tacrolimus. The primary endpoint assessed the proportion of patients achieving complete remission of proteinuria at Week 104, representing two years of treatment. The trial successfully achieved its primary endpoint, with 36.1% of patients receiving obinutuzumab achieving complete remission at Week 104, compared with 5.7% receiving tacrolimus. This difference was statistically significant, with an adjusted difference of 31.1 percentage points and a p-value of less than 0.001. The study also demonstrated improvements in important secondary endpoints. Overall remission, including complete or partial remission, at Week 104 was achieved by 50% of patients receiving obinutuzumab compared with 12.9% receiving tacrolimus. Complete remission at Week 76 was 36.1% in the obinutuzumab group versus 8.6% in the tacrolimus group. The safety findings were consistent with the established safety profile of obinutuzumab, and no new safety signals were identified. The MAJESTY results were presented at the 63rd European Renal Association Congress in June 2026 and published in the New England Journal of Medicine.
Roche Expands Its B-Cell Targeted Immunology Portfolio
The latest FDA approval represents another important milestone in Roche’s strategy to develop targeted treatments for immune-mediated kidney diseases. Gazyva/Gazyvaro is a Type II anti-CD20 monoclonal antibody engineered to promote direct B-cell death and enhance antibody-dependent cellular cytotoxicity (ADCC). By reducing specific B-cell populations involved in abnormal immune responses, the medicine has potential applications across several autoimmune and inflammatory conditions. This is the third FDA approval of Gazyva/Gazyvaro in immune-mediated kidney diseases, following its approvals for idiopathic nephrotic syndrome and lupus nephritis. Roche is also pursuing additional regulatory opportunities for the medicine, including its application for systemic lupus erythematosus (SLE), for which an FDA decision is expected by December 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use has also issued a positive opinion recommending approval for adults with SLE. The company is continuing to submit clinical evidence to other global regulatory authorities, including the European Medicines Agency, for the newly approved pMN indication. Overall, the FDA approval of Gazyva/Gazyvaro marks a major advancement in the treatment of primary membranous nephropathy, providing a targeted therapeutic option supported by Phase III clinical evidence and expanding Roche’s presence in autoimmune kidney disease treatment.
Source: Roche press release



